Metformin Decreases Risk of Basal Cell Carcinoma (BCC)

A study published in the Journal of American Academy of Dermatology finds that Metformin, an anti-diabetic drug, decreases the risk of several human malignancies like liver, pancreas, colon, and breast cancer. A Taiwanese retrospective study demonstrated decreased risk of keratinocyte carcinomas in type 2 diabetes mellitus patients on Metformin, but no differentiation between SCC and BCC was made. Metformin's role in decreasing the risk of BCC was published in a latest study in the Journal of American Academy of Dermatology.

Study Overview

The study was a population case-control study in the Icelandic population using the Icelandic Cancer Registry (ICR) to delineate the relationship between Metformin and the development of BCC, in situ SCC (SCCis), and SCC. A total of 6,880 patients with first-time diagnoses of SCCis, SCC, or BCC and 69,620 population controls between 2003 and 2017 were included in the study. Individuals were considered exposed to Metformin if they had filled at least one prescription of Metformin more than two years before their diagnosis of keratinocyte carcinoma. Multivariate odds ratios (ORs) were calculated using conditional logistic regression.

Results

In total, 4,700 individuals with BCC, 1,167 with SCCis, and 1,013 with invasive SCC were identified and matched with 47,293, 11,961, and 10,367 controls, respectively. Metformin was associated with a lower risk of developing BCC (OR, 0.71; 95% confidence interval [CI], 0.61-0.83), even at low doses. No increased risk of developing SCC was observed. SCCis risk was mildly elevated in the 501-1500 daily dose unit category (OR, 1.40; 95% CI, 1.00-1.96). Individuals older than 60 years had a decreased risk of BCC with Metformin exposure (adjusted OR, 0.69; 95% CI, 0.59-0.82).

The study also shows Metformin's BCC risk-lowering effect is immediate, with only a low dose being needed to see a clinical benefit. Metformin may have less protective effect in younger individuals under 60 years.

Mechanism

Metformin's main antitumor properties are thought to be due to AMP kinase inhibition, leading to the inhibition of the mammalian target of rapamycin. Its mechanism of inhibition of the sonic hedgehog pathway is considered to be the major factor causing a decrease in the risk of BCC.

Conclusion

In conclusion, this study shows an association between decreased risk of BCC and Metformin use in a low-UV environment. Though the effect may be idiosyncratic, only small doses are required to be effective, thereby lowering the risk of side effects due to Metformin.

Source

• Adalsteinsson JA, Muzumdar S, Waldman R, Wu R, Ratner D, Feng H, Ungar J, Silverberg JI, Olafsdottir GH, Kristjansson AK, Tryggvadottir L, Jonasson JG. Metformin is associated with decreased risk of basal cell carcinoma: A whole-population case-control study from Iceland. J Am Acad Dermatol. 2021 Jul;85(1):56-61. doi: 10.1016/j.jaad.2021.02.042.
• Zhang P, Li H, Tan X, Chen L, Wang S. Association of Metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol. 2013;37(3):207-218.
• Tseng CH. Metformin is associated with decreased skin cancer risk in Taiwanese patients with type 2 diabetes. J Am Acad Dermatol. 2018;78(4):694-700.